Trial
NCT03656510
Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Respiratory Syncytial Virus Infections
Intervention
JNJ-53718678
Why stopped
Janssen made the strategic decision to discontinue the CROCuS study. This decision is not based on any safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-04